» Articles » PMID: 23328844

The TGF-β-Smad3 Pathway Inhibits CD28-dependent Cell Growth and Proliferation of CD4 T Cells

Overview
Journal Genes Immun
Date 2013 Jan 19
PMID 23328844
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Transforming growth factor-β (TGF-β) maintains self-tolerance through a constitutive inhibitory effect on T-cell reactivity. In most physiological situations, the tolerogenic effects of TGF-β depend on the canonical signaling molecule Smad3. To characterize how TGF-β/Smad3 signaling contributes to maintenance of T-cell tolerance, we characterized the transcriptional landscape downstream of TGF-β/Smad3 signaling in resting or activated CD4 T cells. We report that in the presence of TGF-β, Smad3 modulates the expression of >400 transcripts. Notably, we identified 40 transcripts whose expression showed Smad3 dependence in both resting and activated cells. This 'signature' confirmed the non-redundant role of Smad3 in TGF-β biology and identified both known and putative immunoregulatory genes. Moreover, we provide genomic and functional evidence that the TGF-β/Smad3 pathway regulates T-cell activation and metabolism. In particular, we show that TGF-β/Smad3 signaling dampens the effect of CD28 stimulation on T-cell growth and proliferation. The impact of TGF-β/Smad3 signals on T-cell activation was similar to that of the mTOR inhibitor Rapamycin. Considering the importance of co-stimulation on the outcome of T-cell activation, we propose that TGF-β-Smad3 signaling may maintain T-cell tolerance by suppressing co-stimulation-dependent mobilization of anabolic pathways.

Citing Articles

The Immunosuppressive Functions of Eosinophils Are Compromised in Patients With Allergic Rhinitis, Particularly Concerning Rab27a Expression.

Liao Y, Li M, Song S, Xu X, Xiao X, Liu Y Immun Inflamm Dis. 2024; 12(12):e70091.

PMID: 39679991 PMC: 11648009. DOI: 10.1002/iid3.70091.


The paradoxical role of transforming growth factor-β in controlling oral squamous cell carcinoma development.

Peng R, Huang Y, Huang P, Liu L, Cheng L, Peng X Cancer Biomark. 2024; 40(3-4):241-250.

PMID: 39213051 PMC: 11380267. DOI: 10.3233/CBM-230354.


TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo.

Kim J, Bose D, Arainga M, Haque M, Fennessey C, Caddell R Nat Commun. 2024; 15(1):1348.

PMID: 38355731 PMC: 10867093. DOI: 10.1038/s41467-024-45555-x.


A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling.

Petersen S, Al Badawy K, Hopkins R, Vu D, Rahmani M, Maia S Mol Ther Oncolytics. 2023; 31:100730.

PMID: 37829123 PMC: 10565558. DOI: 10.1016/j.omto.2023.100730.


Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.

Yadav M, Uikey B, Rathore S, Gupta P, Kashyap D, Kumar C Front Oncol. 2023; 13:1235711.

PMID: 37746258 PMC: 10513393. DOI: 10.3389/fonc.2023.1235711.